Katy McCall is an Associate Director in Molecular Diagnostic Science at AstraZeneca, where they provide expertise and deliverables to clinical trial and diagnostic development teams. Katy's PhD research focused on identifying new biomarkers for septic arthritis, using advanced techniques such as transcriptomics and immunoassays. Previously, Katy worked as a Graduate Scientist at AstraZeneca and as a Clinical Biochemistry intern at the Royal Liverpool and Broadgreen University Hospital NHS Trust. They also contributed to the SABER study, which recruits septic arthritis patients for clinical research in Scotland. Educated at both the University of Liverpool and the University of Glasgow, Katy holds a First Class Bachelor's Degree and a PhD in Precision Medicine.
This person is not in the org chart
This person is not in any teams
This person is not in any offices